SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The SITC Lymphoma CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG will provide recommendations regarding FDA-approved immunotherapies for Hodkin lymphoma and multiple subtypes of non-Hodgkin lymphoma, including rituximab, brentuximab vedotin and axicabtagene ciloleucel, as well as discussion of promising emerging treatment modalities and patient quality of life issues.
Sherry Adkins, RN, MSN, CNS, ANP-C — The University of Texas MD Anderson Cancer Center
Stephen M. Ansell, MD, PhD — Mayo Clinic Cancer Center
Joshua Brody, MD — Icahn School of Medicine at Mount Sinai
Mitchell S. Cairo, MD — New York Medical College At Maria Fareri Children's Hospital
Jonathan W. Friedberg, MD, MMSc — University of Rochester Medical Center
Justin P. Kline, MD — University of Chicago
Ronald Levy, MD — Stanford University
David L. Porter, MD — University of Pennsylvania
Koen Van Besien — Weill Cornell Medicine
Michael Werner — Patient Advocate
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org